Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026
Quantum BioPharma reported Q1 2026 results showing a strengthened balance sheet, with total cash and digital assets rising to $11.2 million and cash burn dropping 60% year-over-year to $1.66 million. Operationally, the company submitted an IND application for its MS drug candidate Lucid-MS, appointed a principal investigator, and signed a binding LOI with Allucent to manage the planned Phase 2 trial. Additionally, a U.S.
Key figures
- Opex reduction
- 13%
- Cash burn reduction
- 60%
- Cash and equivalents
- 9800000
- Crypto portfolio value
- 6500000
- Operating cash burn q1 2026
- 1660000
- Total cash and digital assets
- 11200000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.